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Prosultiamine, a vitamin B1 derivative, has long been used for beriberi neuropathy and Wernicke’s encephalopathy.
Based on the finding that prosultiamine induces apoptosis in human T lymphotropic virus type I (HTLV-I)-infected T cells,
Nakamura et al. conducted a clinical trial of prosultiamine in patients with HTLV-I-associated myelopathy (HAM)/tropical
spastic paraparesis (TSP). In this open-label, single arm study enrolling 24 HAM/TSP patients recently published in BMC
Medicine, oral prosultiamine (300 mg/day for 12 weeks) was found to be effective by neurological, urological and
virological evaluations. Notably, it increased detrusor pressure, bladder capacity and maximum flow rate, and improved
detrusor overactivity and detrusor-sphincter dyssynergia. A significant decrease in HTLV-I copy numbers in peripheral
blood following the treatment provided a rationale for using the drug. The trial has some limitations, such as the small
numbers of participants, the open-label design, the lack of a placebo arm, and the short trial period. Nevertheless, the
observation that such a safe, cheap drug may have excellent therapeutic effects on HAM/TSP, a chronic devastating
illness occurring mainly in developing countries, provides support for future large-scale randomized controlled trials.
Please see related research: http://www.biomedcentral.com/1741-7015/11/182.
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Prosultiamine (Alinamin®), a well-known thiamine de-
rivative, was first developed by Takeda Pharmaceutical
Company in Japan in the 1950s. The drug is a homolog
of allithiamine produced by thiol-type vitamin B1 and
allicin. Prosultiamine is synthesized by substitution of
allyl disulfide with propyl disulfide in the allithiamine
structure, to increase its stability in blood and achieve
efficient absorption from the gut. Prosultiamine is
converted to vitamin B1 after absorption from the gut. The
drug thus enables a long-lasting high blood concentration
of vitamin B1, resulting in efficient access of vitamin B1 to
nervous tissue. Prosultiamine has cured many patients with
vitamin B1 deficiency resulting in beriberi neuropathy andCorrespondence: kira@neuro.med.kyushu-u.ac.jp
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reproduction in any medium, provided the orWernicke’s encephalopathy. Prosultiamine might also
save patients suffering from another devastating neuro-
logic illness associated with a human retrovirus, namely
T lymphotropic virus type I (HTLV-I).
HTLV-I causes not only adult T cell leukemia but
also chronic progressive myelopathy, known as HTLV-
I-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [1]. HAM/TSP is a devastating neurologic
disease causing serious disability, mainly affecting the
middle to lower thoracic spinal cord. Patients with HAM/
TSP thus present with spastic paraparesis owing to the
involvement of the corticospinal tracts. The disease also
induces sphincter disturbance, such as dysuria, pollakisuria,
urinary retention and constipation, and mild sensory im-
pairment of the lower limbs, such as decreased vibratory
sensation and paresthesia. The precise mechanisms under-
lying HAM/TSP remain to be elucidated, but persistentis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tracts and the adjacent white matter of the spinal cord
[2]. HTLV-I mainly infects CD4+ T cells; such HTLV-I-
infected CD4+ T cells are autoproliferative and tend to
infiltrate central nervous system (CNS) tissue [3]. Some au-
thors have hypothesized the existence of ‘bystander tissue
damage’ during the chronic inflammatory process when
cytotoxic CD8+ T cells continuously kill HTLV-I-infected
CD4+ T cells infiltrating the CNS [2,4].
In HAM/TSP patients, HTLV-I proviral DNA loads
in peripheral blood are markedly increased despite the
presence of abundant cytotoxic T cells against HTLV-I
[5,6]. Therefore, it is assumed to be beneficial to reduce the
number of HTLV-I-infected T cells for treatment of HAM/
TSP. Indeed, interferon α (IFNα), a potent drug against
the disease, can decrease HTLV-I proviral DNA loads
in peripheral blood [7]. Although IFNα is effective,
long-term efficacy is modest and adverse effects are
relatively frequent and occasionally severe, which makes it
difficult to administer the drug for many years. Other im-
munotherapies, such as corticosteroids [1], plasmapheresis
[8], and intermittent high-dose vitamin C [9], exhibit only
short-term benefits. Long-term administration of immuno-
suppressants, such as azathioprine and mizoribine, showed
only limited efficacy in a minority of HAM/TSP patients
[10]. HAM/TSP is relatively frequently encountered in
areas encompassing developing countries, such as equator-
ial Africa, the Caribbean, Central and South America, the
Middle East, and Melanesia [11]. Because curative treat-
ment of HAM/TSP is lacking and no vaccine is available, a
low-cost drug with tolerable safety profiles for long-term
usage is of paramount importance.
Recently, Nakamura et al. [12] discovered that pro-
sultiamine induces apoptosis of HTLV-I-infected T
cells; therefore, they conducted a clinical trial of oral
prosultiamine in HAM/TSP patients to obtain proof of
concept for the drug [13].
Clinical trial results of prosultiamine in HAM/TSP patients
Study design
The study recently published in BMC Medicine by
Nakamura et al. [13] was an open-label, single arm
study enrolling 24 patients with HAM/TSP, aged 31 to
80 years. The disease duration ranged from 3 to 51 years,
with an average of 20.9 years. Prosultiamine 300 mg was
administered orally once daily for 12 weeks. Effects were
assessed in three ways, neurological, urological and viro-
logical, every 4 weeks. Neurological assessments included
the time required for a 10 meter walk, and that required
for walking down a flight of stairs, and the modified
Ashworth scale (MAS) for spasticity grading of the
lower extremities besides full neurological examinations.
Detailed urological evaluations were carried out employing
the Nocturia Quality of Life (N-QoL) questionnaire andurodynamic studies to measure bladder capacity, detrusor
pressure, maximum flow rate, detrusor overactivity, and
detrusor-sphincter dyssynergia. Peripheral blood HTLV-I
proviral DNA loads were measured by real-time quantita-
tive polymerase chain reaction.
Main findings
Prosultiamine improved lower limb spasticity in 80% of
the patients (by more than 1 grade for the degree of
spasticity on MAS), which almost coincided with im-
provements in the times required for a 10 meter walk
(4.4% to 36.8% decrease in 11 patients) and walking down
a flight of stairs (2.3% to 53.2% decrease in 10 patients).
Remarkably, both the N-QoL scores and urinary function
tests as evaluated by urodynamic studies were signifi-
cantly improved by the treatment compared with base-
line levels; there were increases in detrusor pressure
(from 16.8 to 27.5 cm/H2O on average) and bladder cap-
acity (from 341.3 to 391.0 ml on average), and maximum
flow rate (from 7.5 to 10.2 ml/s on average) together
with improvements in detrusor overactivity (68.8% of
the patients) and detrusor-sphincter dyssynergia (45.5%
of the patients). Importantly, HTLV-I copy numbers in 104
peripheral blood mononuclear cells (PMBCs) decreased
significantly after treatment compared with pretreatment
levels (from 2,127 to 1,799 on average), with some patients
reaching a 30% to 50% decrease. Only three patients
complained of mild epigastric discomfort during treatment;
otherwise, no side effects were observed.
Interpretation of the trial findings
The number of participants in the present trial was small
and the trial was open-label without a placebo arm; there-
fore, the current observations should be interpreted with
caution and the findings should be confirmed by a large-
scale, randomized, double-blind, placebo-controlled study
in the future. Nonetheless, the improvement in urodynamic
study findings is striking and could provide some proof of
concept for the use of prosultiamine in HAM/TSP patients.
Although placebo effects in the improved motor perform-
ance could not be fully eliminated, the urodynamic study
findings support the notion that oral vitamin B1 derivatives
have real therapeutic effects on HAM/TSP. The coinci-
dence of the HTLV-I proviral DNA reduction in PBMCs by
the drug with therapeutic efficacy may also support such a
notion. Such a coincidence was also observed with IFNα
[7]. The same authors’ research group previously reported
that prosultiamine induces apoptosis of HTLV-I-infected
cells, possibly through disruption of the intracellular redox
system via reaction of the disulfide moieties in the drug
with thiol-containing intracellular molecules [12]. Given
that, in two recent studies, a reverse transcriptase in-
hibitor [14] and a histone deacetylase enzyme inhibitor
[15] targeting HTLV-I failed to reduce copy numbers,
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after 3 months of administration of prosultiamine in the
present study is noteworthy. However, the decrease in
HTLV-I proviral DNA loads was modest, albeit significant.
Why could such a small decrease in peripheral HTLV-I
loads induce measurable clinical benefits? Vitamin B1 easily
penetrates into the CNS where it might reduce persist-
ent inflammation via induction of apoptosis of infiltrated
HTLV-I-infected cells that express the bcl-2 oncoprotein
and are usually resistant to apoptosis [4]. It is critical
to investigate whether the elevation of IP-10 and other
proinflammatory cytokines in cerebrospinal fluid [16] is
downmodulated following treatment with prosultiamine. It
is also urgently necessary to clarify if years of prosultiamine
administration could further reduce HTLV-I copy numbers.
In this case, oral prosultiamine might be classified as a
first-line drug for the long-term treatment of HAM/
TSP, considering its excellent safety profile.
Conclusions
Oral prosultiamine could safely alleviate HAM/TSP as
evidenced by motor function evaluation and urodynamic
studies, coinciding with a modest decrease in HTLV-I copy
numbers in PBMCs. The drug appears to be promising, but
the long-term benefits of the drug remain to be established
by a large-scale, randomized, controlled study. The results
of the present study encourage such investigations.
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